AgingResearch.NewsJoin free

Bioio

CompanyUnited States

Bioio develops one asset, preclinical (BIOIO-1001 in amyotrophic lateral sclerosis). Mostly small molecule; based in the United States.

1
Asset
Furthest stage
Preclinical
4
Grants
0
Trials
0
Signals

Pipeline

1

  • BIOIO-1001

    Modulates mTOR/insulin and NAD+ pathways through SIRT3-centered lipid metabolism, reducing inflammation and fibrosis in preclinical models.

    Preclinical, Small molecule, amyotrophic lateral sclerosis, metabolic dysfunction-associated steatohepatitis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • People1
  • Similar companies6

Papers

Intelligence